SK6022001A3 - 2,4-disubstituted triazine derivatives with anti hiv activity - Google Patents

2,4-disubstituted triazine derivatives with anti hiv activity Download PDF

Info

Publication number
SK6022001A3
SK6022001A3 SK602-2001A SK6022001A SK6022001A3 SK 6022001 A3 SK6022001 A3 SK 6022001A3 SK 6022001 A SK6022001 A SK 6022001A SK 6022001 A3 SK6022001 A3 SK 6022001A3
Authority
SK
Slovakia
Prior art keywords
cyano
formula
alkyl
optionally substituted
substituted
Prior art date
Application number
SK602-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Corte Bart De
Jonge Marc Rene De
Jan Heeres
Paul Adriaan Jan Janssen
Robert W Kavash
Lucien Maria Henricus Koymans
Michael Joseph Kukla
Donald William Ludovici
Aken Koen Jeanne Alfons Van
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SK6022001A3 publication Critical patent/SK6022001A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/46—One nitrogen atom with oxygen or sulfur atoms attached to the two other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y10S977/775—Nanosized powder or flake, e.g. nanosized catalyst
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK602-2001A 1998-11-10 1999-11-04 2,4-disubstituted triazine derivatives with anti hiv activity SK6022001A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10779998P 1998-11-10 1998-11-10
EP99203128 1999-09-24
PCT/EP1999/008688 WO2000027828A2 (fr) 1998-11-10 1999-11-04 Derives de triazine 2,4-disubstitues

Publications (1)

Publication Number Publication Date
SK6022001A3 true SK6022001A3 (en) 2002-01-07

Family

ID=26153374

Family Applications (1)

Application Number Title Priority Date Filing Date
SK602-2001A SK6022001A3 (en) 1998-11-10 1999-11-04 2,4-disubstituted triazine derivatives with anti hiv activity

Country Status (35)

Country Link
US (2) US6638932B1 (fr)
EP (1) EP1129079B1 (fr)
JP (1) JP2002529457A (fr)
KR (1) KR100620402B1 (fr)
CN (1) CN1207290C (fr)
AP (1) AP1636A (fr)
AR (1) AR021137A1 (fr)
AT (1) ATE315031T1 (fr)
AU (1) AU764472B2 (fr)
BG (1) BG65160B1 (fr)
BR (1) BR9915176A (fr)
CA (1) CA2351203C (fr)
CY (1) CY1105596T1 (fr)
CZ (1) CZ20011532A3 (fr)
DE (1) DE69929354T2 (fr)
DK (1) DK1129079T3 (fr)
EA (1) EA004501B1 (fr)
EE (1) EE200100253A (fr)
ES (1) ES2257081T3 (fr)
HK (1) HK1038232A1 (fr)
HR (1) HRP20010310A2 (fr)
HU (1) HUP0104395A3 (fr)
ID (1) ID28545A (fr)
IL (2) IL143024A0 (fr)
MY (1) MY126781A (fr)
NO (1) NO319788B1 (fr)
NZ (1) NZ510919A (fr)
OA (1) OA11675A (fr)
PL (1) PL196523B1 (fr)
PT (1) PT1129079E (fr)
SI (1) SI1129079T1 (fr)
SK (1) SK6022001A3 (fr)
TR (1) TR200101319T2 (fr)
TW (1) TW541305B (fr)
WO (1) WO2000027828A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0104395A3 (en) * 1998-11-10 2003-02-28 Janssen Pharmaceutica Nv 2,4-disubstituted triazine derivatives with anti hiv activity, process for their preparation and medicaments containing them
DE19945982A1 (de) 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
WO2001085700A2 (fr) 2000-05-08 2001-11-15 Janssen Pharmaceutica N.V. Inhibiteurs de la replication du vih
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
ATE402152T1 (de) * 2003-02-07 2008-08-15 Janssen Pharmaceutica Nv Hiv-inhibierende1,2,4-triazine
CN101035773B (zh) 2004-08-10 2012-06-06 詹森药业有限公司 抑制hiv的1,2,4-三嗪-6-酮衍生物
GB201204756D0 (en) * 2012-03-19 2012-05-02 Lewi Paulus J Triazines with suitable spacers for treatment and/or prevention of HIV infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4927592B1 (fr) * 1970-05-13 1974-07-18
BE754242A (fr) 1970-07-15 1971-02-01 Geigy Ag J R Diamino-s-triazines et dinitro-s-triazines
US4650867A (en) * 1985-03-26 1987-03-17 Ciba-Geigy Corporation Process for the preparation of 2,4,6-tris(aminophenylamino)triazines
JPH02308248A (ja) 1989-05-24 1990-12-21 Fuji Photo Film Co Ltd アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料
EP0723533A1 (fr) 1993-10-12 1996-07-31 The Du Pont Merck Pharmaceutical Company 1n-alkyle-n-arylpyrimidinamines et leurs derives
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
ATE245641T1 (de) 1998-02-17 2003-08-15 Tularik Inc Antivirale pyrimidinderivate
HUP0104395A3 (en) * 1998-11-10 2003-02-28 Janssen Pharmaceutica Nv 2,4-disubstituted triazine derivatives with anti hiv activity, process for their preparation and medicaments containing them

Also Published As

Publication number Publication date
IL143024A (en) 2006-06-11
NO319788B1 (no) 2005-09-12
BG105419A (en) 2001-11-30
SI1129079T1 (sl) 2006-06-30
AU764472B2 (en) 2003-08-21
US7015221B2 (en) 2006-03-21
NZ510919A (en) 2003-11-28
AR021137A1 (es) 2002-06-12
OA11675A (en) 2005-01-12
CN1325387A (zh) 2001-12-05
AP1636A (en) 2006-07-17
DE69929354T2 (de) 2006-09-14
EA004501B1 (ru) 2004-04-29
AU1046200A (en) 2000-05-29
BG65160B1 (bg) 2007-04-30
EE200100253A (et) 2002-12-16
KR20010075234A (ko) 2001-08-09
CA2351203A1 (fr) 2000-05-18
US20050277641A1 (en) 2005-12-15
IL143024A0 (en) 2002-04-21
US6638932B1 (en) 2003-10-28
BR9915176A (pt) 2001-08-14
CZ20011532A3 (cs) 2001-10-17
EA200100534A1 (ru) 2001-10-22
HUP0104395A3 (en) 2003-02-28
HK1038232A1 (en) 2002-03-08
EP1129079A2 (fr) 2001-09-05
WO2000027828A2 (fr) 2000-05-18
PL348145A1 (en) 2002-05-06
ID28545A (id) 2001-05-31
NO20011934D0 (no) 2001-04-19
CA2351203C (fr) 2009-03-24
CY1105596T1 (el) 2010-07-28
MY126781A (en) 2006-10-31
DE69929354D1 (de) 2006-03-30
EP1129079B1 (fr) 2006-01-04
PT1129079E (pt) 2006-05-31
CN1207290C (zh) 2005-06-22
HUP0104395A2 (hu) 2002-04-29
PL196523B1 (pl) 2008-01-31
TR200101319T2 (tr) 2001-10-22
NO20011934L (no) 2001-04-19
HRP20010310A2 (en) 2002-06-30
JP2002529457A (ja) 2002-09-10
TW541305B (en) 2003-07-11
KR100620402B1 (ko) 2006-09-13
DK1129079T3 (da) 2006-05-15
WO2000027828A3 (fr) 2000-09-21
ES2257081T3 (es) 2006-07-16
ATE315031T1 (de) 2006-02-15

Similar Documents

Publication Publication Date Title
JP3635238B2 (ja) Ｈｉｖの複製を阻害するピリミジン類
SK6022001A3 (en) 2,4-disubstituted triazine derivatives with anti hiv activity
MXPA01003644A (en) 2,4-disubstituted triazine derivatives
MXPA01003646A (en) Hiv replication inhibiting pyrimidines
ZA200103768B (en) 2,4-Disubstituted triazine derivatives.